Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 4/20 | 0.42 |
| ▸ | CYP2D6 | P10635 | 2/20 | 0.42 |
| ▸ | SPHK1 | Q9NYA1 | 2/20 | 0.42 |
| ▸ | GMNN | O75496 | 1/20 | 0.42 |
| ▸ | POLB | P06746 | 1/20 | 0.42 |
| ▸ | THPO | P40225 | 1/20 | 0.42 |
| ▸ | MTOR | P42345 | 1/20 | 0.42 |
| ▸ | BLM | P54132 | 1/20 | 0.42 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.42 |
| ▸ | TP53 | P04637 | 1/20 | 0.42 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.42 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.42 |
| ▸ | MAPT | P10636 | 1/20 | 0.42 |
| ▸ | CETP | P11597 | 1/20 | 0.42 |
| ▸ | HTT | P42858 | 1/20 | 0.42 |
| ▸ | UBE2N | P61088 | 1/20 | 0.42 |
| ▸ | USP2 | O75604 | 1/20 | 0.37 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.37 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.37 |
| ▸ | MEN1 | O00255 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL28446431 | 0.90 | LMNA (0.37) | LMNACYP2D6SPHK1GMNNPOLB | |
| SCHEMBL10767247 | 0.82 | LMNA (0.41) | LMNACYP2D6SPHK1GMNNPOLB | |
| SCHEMBL6241898 | 0.82 | SPHK1 (0.48) | LMNACYP2D6SPHK1GMNNPOLB | |
| SCHEMBL28719154 | 0.82 | SPHK1 (0.48) | LMNACYP2D6SPHK1GMNNPOLB | |
| SCHEMBL9442815 | 0.82 | SPHK1 (0.48) | LMNACYP2D6SPHK1GMNNPOLB | |
| SCHEMBL2590619 | 0.80 | CYP2D6 (0.44) | LMNACYP2D6SPHK1GMNNPOLB | |
| SCHEMBL7867569 | 0.80 | CYP2D6 (0.44) | LMNACYP2D6SPHK1GMNNPOLB | |
| SCHEMBL29199484 | 0.77 | CYP2D6 (0.38) | LMNACYP2D6SPHK1GMNNPOLB | |
| SCHEMBL31738650 | 0.77 | CYP2D6 (0.38) | LMNACYP2D6SPHK1GMNNPOLB | |
| SCHEMBL28400584 | 0.76 | SMPD1 (0.41) | LMNACYP2D6SPHK1GMNNPOLB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 66 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260071218-A1 | Oral Delivery of Antisense Conjugates Targeting PCSK9 | CIVI BIOPHARMA INC (US) | 2026-03-12 | — | — | US | disclosed |
| EP-4705455-A1 | COMPOUNDS AND METHODS FOR TREATING HUMAN SUBJECTS | Stoke Therapeutics, Inc. (US) | 2026-03-11 | — | — | EP | disclosed |
| EP-4705454-A2 | COMPOUNDS AND METHODS FOR TREATING HUMAN SUBJECTS | Stoke Therapeutics, Inc. (US) | 2026-03-11 | — | — | EP | disclosed |
| US-20260055409-A1 | COMPOUNDS AND METHODS FOR TREATING HUMAN SUBJECTS | STOKE THERAPEUTICS INC (US) | 2026-02-26 | — | — | US | disclosed |
| US-12421516-B2 | Antisense oligomers targeting PCSK9 | ROCHE INNOVATION CENTER COPENHAGEN A/S (DK) | 2025-09-23 | — | — | US | disclosed |
| US-12291708-B2 | Oral delivery of antisense conjugates targeting PCSK9 | CIVI BIOPHARMA, INC. (US) | 2025-05-06 | — | — | US | disclosed |
| WO-2024229421-A1 | COMPOUNDS AND METHODS FOR TREATING HUMAN SUBJECTS | STOKE THERAPEUTICS, INC. (US) | 2024-11-07 | — | — | WO | disclosed |
| WO-2024227085-A2 | COMPOUNDS AND METHODS FOR TREATING HUMAN SUBJECTS | STOKE THERAPEUTICS, INC. (US) | 2024-10-31 | — | — | WO | disclosed |
| US-20240084307-A1 | ANTISENSE OLIGOMERS TARGETING PCSK9 | ROCHE INNOVATION CENTER COPENHAGEN A/S (DK) | 2024-03-14 | — | — | US | disclosed |
| US-20240067965-A1 | ORAL DELIVERY OF ANTISENSE CONJUGATES TARGETING PCSK9 | CIVI BIOPHARMA INC (US) | 2024-02-29 | — | — | US | disclosed |
| US-7608705-B2 | nucleobases are cytosine groups or mimetics; modified with polyethyleneglycol or a tocopheryl group; useful in inhibiting proliferation of pancreatic tumors | UNIVERSITATSKLINIKUM SCHLESWIG-HOLSTEIN (DE) | 2009-10-27 | — | — | US | disclosed |
| US-20090203132-A1 | PYRROLIDINYL GROUPS FOR ATTACHING CONJUGATES TO OLIGOMERIC COMPOUNDS | ISIS PHARMACEUTICALS, INC. | 2009-08-13 | — | — | US | disclosed |
| US-20080199960-A1 | Methods for the Delivery of Oligomeric Compounds | K.U. LEUVEN RESEARCH AND DEVELOPMENT (BE) | 2008-08-21 | — | — | US | disclosed |
| WO-2006031461-A2 | PYRROLIDINYL GROUPS FOR ATTACHING CONJUGATES TO OLIGOMERIC COMPOUNDS | ISIS PHARMACEUTICALS, INC. (US) | 2006-03-23 | — | — | WO | disclosed |
| US-20050119470-A1 | Conjugated oligomeric compounds and their use in gene modulation | ISIS PHARMACEUTICALS, INC. | 2005-06-02 | — | — | US | disclosed |
| US-20050019761-A1 | Oligonucleotides, agents containing these oligonucleotides, and the use thereof | UNIVERSITATSKLINIKUM SCHLESWIG-HOLSTEIN (DE) | 2005-01-27 | — | — | US | disclosed |
| WO-2004044141-A2 | CONJUGATED OLIGOMERIC COMPOUNDS AND THEIR USE IN GENE MODULATION | ISIS PHARMACEUTICALS, INC. (US) | 2004-05-27 | — | — | WO | disclosed |
| EP-1326878-A2 | OLIGONUCLEOTIDES, AGENTS CONTAINING THESE OLIGONUCLEOTIDES, AND THE USE THEREOF | Bayer, Ernst, Prof. Dr. (DE) | 2003-07-16 | — | — | EP | disclosed |
| WO-2002026754-A9 | OLIGONUCLEOTIDES, AGENTS CONTAINING THESE OLIGONUCLEOTIDES, AND THE USE THEREOF | BAYER ERNST (DE) | 2003-05-15 | — | — | WO | disclosed |
| WO-2002026754-A2 | OLIGONUCLEOTIDES, AGENTS CONTAINING THESE OLIGONUCLEOTIDES, AND THE USE THEREOF | BAYER ERNST (DE) | 2002-04-04 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12421516-B2 | Antisense oligomers targeting PCSK9 | PCSK9, PCSK7, PCSK6 | LMNA 199/4885CYP2D6 4600/4885SPHK1 491/4885 |
| US-20090203132-A1 | PYRROLIDINYL GROUPS FOR ATTACHING CONJUGATES TO OLIGOMERIC COMPOUNDS | PHAX, RIOX2, RNMT | LMNA 4212/4885CYP2D6 4258/4885SPHK1 4569/4885 |
| US-20260071218-A1 | Oral Delivery of Antisense Conjugates Targeting PCSK9 | PCSK9, ALPI, SLC10A2 | LMNA 294/4885CYP2D6 287/4885SPHK1 2650/4885 |
| US-20240067965-A1 | ORAL DELIVERY OF ANTISENSE CONJUGATES TARGETING PCSK9 | PCSK9, SCD5, PCSK7 | LMNA 572/4885CYP2D6 2462/4885SPHK1 553/4885 |
| US-20260055409-A1 | COMPOUNDS AND METHODS FOR TREATING HUMAN SUBJECTS | CYFIP1, SYNGR2, CYFIP2 | LMNA 2018/4885CYP2D6 4356/4885SPHK1 4104/4885 |
| US-12291708-B2 | Oral delivery of antisense conjugates targeting PCSK9 | PCSK9, SCD5, PCSK7 | LMNA 572/4885CYP2D6 2462/4885SPHK1 553/4885 |
| US-20050119470-A1 | Conjugated oligomeric compounds and their use in gene modulation | PHAX, SNRPE, RRP1B | LMNA 2742/4885CYP2D6 1836/4885SPHK1 4348/4885 |
| US-20240084307-A1 | ANTISENSE OLIGOMERS TARGETING PCSK9 | PCSK9, PCSK7, PCSK6 | LMNA 199/4885CYP2D6 4600/4885SPHK1 491/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.